Amanta Healthcare Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Amanta Healthcare Ltd filed with BSE on 21 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Amanta Healthcare reported FY26 revenue of INR288 crores and EBITDA of INR63 crores at around 22% margin, with PAT growing over 42% year-on-year. Management said the SteriPort platform contributed nearly 42% of revenue from operations and detailed a capacity expansion from 6.6 crore to roughly 12 crore bottles per year expected to be commissioned by June 20. Management also discussed rising polymer input costs of 60-70%, which they said have been offset through price revisions, and outlined debt reduction with the debt-to-equity ratio improving from 3x to nearly 1x.
Numbers mentioned
Revenue: INR288 crores (FY26)
p. 3
“we are delighted to report revenue of INR288 crores and EBITDA of INR63 crores, while maintaining the EBITDA margin at around 22%”
Bhavesh Patel, page 3 of the filed PDF · View the filing
EBITDA margin: around 22% (FY26)
p. 3
“we are delighted to report revenue of INR288 crores and EBITDA of INR63 crores, while maintaining the EBITDA margin at around 22%”
Bhavesh Patel, page 3 of the filed PDF · View the filing
PAT growth: over 42% year-on-year (FY26)
p. 3
“our profitability improved significantly with PAT growing by over 42% year-on-year, supported by better operating leverage and meaningful reduction in finance cost”
Bhavesh Patel, page 3 of the filed PDF · View the filing
SteriPort revenue contribution: nearly 42% of revenue from operations (FY26)
p. 3
“Our SteriPort platform, a product that continues to gain strong traction in the market, contributes nearly 42% of the revenue from operations”
Bhavesh Patel, page 3 of the filed PDF · View the filing
Revenue: about INR77 crores (Q4 FY26)
p. 5
“For the quarter March ‘26, revenue stood at about INR77 crores, registering a 6.8% growth on compared to the previous quarter on year-on-year basis”
Paras Mehta, page 5 of the filed PDF · View the filing
Net profit: INR5.5 crores, up by 28% year-on-year (Q4 FY26)
p. 5
“Net profit for the quarter four increased to INR5.5 crores, up by 28% on year-to-year basis”
Paras Mehta, page 5 of the filed PDF · View the filing
Annualized PAT: INR15 crores versus INR10.5 crores last year (FY26)
p. 5
“Now with this result, we have INR15 crores annualized PAT as compared to INR10.5 crores last year”
Paras Mehta, page 5 of the filed PDF · View the filing
PAT margin: 7% for Q4, 5% for full year (Q4 FY26 / FY26)
p. 5
“PAT margin for quarter four stood at 7%, while full year ‘26 PAT margin expanded by 100 basis points on year-on-year basis to 5%”
Paras Mehta, page 5 of the filed PDF · View the filing
Debt-to-equity ratio: improved from 3x to nearly 1x (last three years)
p. 4
“Over the last three years, we have significantly reduced leverage with our debt-to-equity ratio improving from 3x to nearly 1x today”
Bhavesh Patel, page 4 of the filed PDF · View the filing
Total debt: INR234 crore in balance sheet, INR204 crore currently (as on call date)
p. 10
“if you look at the balance sheet '26 March numbers, you will see the debt of INR234 crore total debt, but as on today while we are talking, it is INR204 crore”
Paras Mehta, page 10 of the filed PDF · View the filing
Export share of revenue: around 39% (FY26)
p. 16
“in year '25-'26, our total export was around 39% of the revenue”
Bhavesh Patel, page 16 of the filed PDF · View the filing
Working capital cycle: 120 to 125 days (current)
p. 15
“our current working capital cycle is about 100-plus days. To be precise, it will be ranging between 120 to 125 days”
Paras Mehta, page 15 of the filed PDF · View the filing
Contract manufacturing share of revenue: 8% to 10% (current)
p. 18
“Contract manufacturing must be around 8% to 10% of our revenue and in terms of percentage it may further reduce, because SteriPort will expand”
Bhavesh Patel, page 18 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
SteriPort capacity — roughly 12 crore bottles per year
stated firmly by Bhavesh Patel
p. 3
“we are now expanding capacity from 6.6 crore bottles per year to roughly 12 crore bottles per year”
Bhavesh Patel, page 3 of the filed PDF · View the filing
SteriPort line commissioning — operational by 20th June · June 2026
stated firmly by Bhavesh Patel
p. 7
“So we are hopeful that by 20th June we should be able to get operational.”
Bhavesh Patel, page 7 of the filed PDF · View the filing
Solar project cost savings — roughly INR75 lakh a month · from 25th or 30th May
stated firmly by Bhavesh Patel
p. 7
“So by 25th May or maybe 30th May, we should start accruing the benefit of that at the rate of INR75 lakh a month”
Bhavesh Patel, page 7 of the filed PDF · View the filing
EBITDA margin — 24% to 25%
stated as an aspiration by Paras Mehta
p. 14
“combining the new and the existing, on an average basis we will be expecting between 24% to 25% EBITDA margin going forward”
Paras Mehta, page 14 of the filed PDF · View the filing
PAT margin — improving by at least 3%
stated conditionally by Paras Mehta
p. 14
“Once we leverage in the current year then going forward, it will be improving by at least 3%.”
Paras Mehta, page 14 of the filed PDF · View the filing
Debt refinancing — INR30 crores to INR40 crores of debt replaced with lower interest rate · next six months
stated as an aspiration by Bhavesh Patel
p. 10
“I believe that there would be -- we should still be able to replace around INR30 crores to INR40 crores of debt with lower interest rate in next six months also”
Bhavesh Patel, page 10 of the filed PDF · View the filing
SVP line commissioning — October, November or December this year
stated firmly by Bhavesh Patel
p. 15
“So the way I see it, SVP line will be commissioned in October, November or December this year.”
Bhavesh Patel, page 15 of the filed PDF · View the filing
Working capital cycle — about 110 days · near future
stated as an aspiration by Paras Mehta
p. 15
“and we expect it to go about 110 days in near future”
Paras Mehta, page 15 of the filed PDF · View the filing
SteriPort market share of two-port system — 20% to 25% · by 2030
stated as an aspiration by Bhavesh Patel
p. 9
“we envisage to have around 20% to 25% market share because targeting higher market share in generic space doesn't make sense”
Bhavesh Patel, page 9 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said polymer prices rose 60-70%, prices were revised with roughly INR2 per bottle impact on SteriPort, and no resistance has been encountered.
Answered by Bhavesh Patel
Asked by Akash Jain: How is the company managing raw material price and supply challenges, and will SteriPort face downgrading pressure due to price increases?
p. 6
“The total impact could be around INR2 per bottle in SteriPort.”
Bhavesh Patel, page 6 of the filed PDF · View the filing
Management clarified the benefit of price revision on old inventory would show up in Q1, not Q4.
Answered by Bhavesh Patel
Asked by Akash Jain: Is there an inventory gain benefit this quarter from lower-cost raw material inventory?
p. 7
“I think we will get -- that benefit would be visible in Q1, not in Q4 of last year.”
Bhavesh Patel, page 7 of the filed PDF · View the filing
Management described equipment installation, trials, and expected qualification and validation timeline leading to operations by 20th June.
Answered by Bhavesh Patel
Asked by Akash Jain: What is the status of the SteriPort expansion and when will commercial production start?
p. 7
“So the final mopping up operation is going on right now in terms of finishing. That would take another 10 days to 15 days.”
Bhavesh Patel, page 7 of the filed PDF · View the filing
Management described IV fluid demand growing 8-10% annually and two-port system growing faster at 12-13% due to conversion from conventional packs.
Answered by Bhavesh Patel
Asked by Rishabh Shah: How does management see demand-supply dynamics evolving in the two-port/LVP segment given supplier forward integration?
p. 8
“the two-port system will grow at 12% to 13% because there is conversion happening from conventional pack to two-port system”
Bhavesh Patel, page 8 of the filed PDF · View the filing
Management said the finance cost declined due to debt repayment and cheaper debt, with 90% of borrowing now in single-digit interest rates.
Answered by Bhavesh Patel
Asked by Aniket Nikumb: What is the outlook for finance costs given the recent refinancing?
p. 10
“So I think today I don't think we have I think 90% borrowing is in single-digit.”
Bhavesh Patel, page 10 of the filed PDF · View the filing
Management explained there will be an inventory buildup phase before reaching equilibrium, spanning roughly 9-10 months.
Answered by Bhavesh Patel
Asked by Aniket Nikumb: Will the new capacity run at full utilization from day one?
p. 11
“So, this typically 9 months to 10 months cycle.”
Bhavesh Patel, page 11 of the filed PDF · View the filing
Management said SteriPort is expected to run at about 27% EBITDA margin versus 22% for existing portfolio, blending to 24-25% going forward.
Answered by Paras Mehta
Asked by Nupur: What EBITDA margin is expected on SteriPort versus existing products, and is 24-25% sustainable?
p. 14
“The new product line is expected to have about 27% EBITDA margin only for SteriPort.”
Paras Mehta, page 14 of the filed PDF · View the filing
Management stated export share rose to around 39% of revenue with Thailand, UK, Philippines, South Sudan among top markets.
Answered by Bhavesh Patel
Asked by Saket Saurabh: What was the export share for FY26 and top export countries?
p. 16
“So, in year '25-'26, our total export was around 39% of the revenue.”
Bhavesh Patel, page 16 of the filed PDF · View the filing
Management explained SteriPort withstands higher temperatures and has greater transparency and tensile strength than Eurohead/PE containers.
Answered by Bhavesh Patel
Asked by Saket Saurabh: How does SteriPort compare technically to Eurohead containers used by competitors?
p. 17
“SteriPort has a polymer which can withstand 121.1 degree centigrade and more, whereas the Eurohead containers, which they call Eurohead, they use polyethylene.”
Bhavesh Patel, page 17 of the filed PDF · View the filing
Risks flagged
Rising polymer and plastic input costs due to global crude price increases
p. 6
“the polymer prices have gone up by roughly 60% to 70%”
Bhavesh Patel, page 6 of the filed PDF · View the filing
Polyethylene price volatility affecting the conventional bottle sub-segment more than SteriPort
p. 6
“The polyethylene prices are more volatile and the gross consumption of plastic in polyethylene container is even more than what we consume in SteriPort.”
Bhavesh Patel, page 6 of the filed PDF · View the filing
One-sided nature of hospital chain contracts limiting negotiating leverage
p. 12
“So, it is pretty much one-sided and therefore, we have never ever entered into any contract with any hospital chain.”
Bhavesh Patel, page 12 of the filed PDF · View the filing
Lag between raw material cost changes and price adjustments could create margin timing mismatches
p. 7
“So there would be a lag to some extent, but usually once the price go up by say let's say INR2, they will not come down by INR2, they will come down by say INR0.75, INR1, something like that.”
Bhavesh Patel, page 7 of the filed PDF · View the filing
Credit rating constrained until project implementation phase is complete
p. 10
“they said that we cannot give you better rating till you are in a project implementation phase”
Bhavesh Patel, page 10 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.